The Galien Foundation has revealed its latest nominees for the 2021 Prix Galien USA Award highlighting innovations in biotechnology, pharmaceutical agents, medical technology and digital health products. Entrants to the competition must have received FDA approval within the past five years and demonstrate exceptional therapeutic potential. The Galien Foundation does not use financial data to…
Nubeqa offers promise to prostate cancer patients
FDA indicates Nubeqa (darolutamide) to treat patients with non-metastatic castration-resistant prostate cancer. Bayer and Orion Corp. jointly developed the drug, which FDA approved in 2019. The approval came after FDA reviewed results from the Phase 3 ARAMIS study, which tested Nubeqa with androgen deprivation therapy (ADT) in patients with prostate cancer. The drug has continued to…